Product Introduction

GF109203X

GF109203X is a potent **PKC** inhibitor with **IC50** of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor.

Technical Data:

Molecular Weight (MW):	412.48	
Formula:	$C_{25}H_{24}N_4O_2$	
Solubility (25°C) * <1 mg/ml means slightly soluble or insoluble:	DMSO 82 mg/mL	
	Water <1 mg/mL	
	Ethanol <1 mg/mL	
Purity:	>98%	
Storage:	3 years -20℃Powder	
	6 months-80℃in DMSO	
CAS No.:	133052-90-1	

Biological Activity

GF109203X, as an ATP-competitive PKC inhibitor, prevents platelet aggregation induced by stimuli that activate PKC, and has the potential as a tool for studying the involvement of PKC in signal transduction pathways. [1] GF 109203X produces reversal activity on P-glycoprotein and MRP -mediated multidrug resistance. [2] [3] PKC inhibition by GF109203X significantly reduces carbachol-stimulated ERK1/2 activation and the subsequent proliferation of SNU-407 colon cancer cells. [4]

Greater selectivity than PKC inhibitor staurosporine. GF109203X is a chemical probe for studying PKC signal transduction pathways. Potential for use in a variety of cancers.

References

[1] Toullec D, et al. J Biol Chem. 1991, 266(24), 15771-15781.

[2] Gekeler V, et al. Br J Cancer. 1996, 74(6), 897-905.

[3] Gekeler V, et al. Biochem Biophys Res Commun. 1995, 206(1), 119-126.

[4] Park YS, et al. Mol Cell Biochem. 2012, 370(1-2), 191-198.

Note： Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer’s risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.